
In compliance with article 118 "authorization of advertising to the public" of the legislative decree of 24 April 2006, number 219
INDICATIONS
Gingivitis, stomatitis, oropharyngitis, adjuvant in the treatment of alveolar pyorrhea.
CONTRAINDICATIONS
Hypersensitivity to the active substances or to any of the excipients listed in paragraph 6.1. Not to be used in children under 12 years of age. With the topical application of salicylic acid there is a hypothetical risk of inducing Reye's syndrome. Reye's syndrome has been observed after oral administration of higher doses of salicylic acid or acetylsalicylic acid in children. There have been no confirmed cases of Reye's Syndrome associated with the use of Pyralvex. Due to the ethanol content the medicine is not suitable for patients with alcoholism.
WARNINGS AND PRECAUTIONS FOR USE
Do not exceed the recommended application frequency. Salicylate toxicity may occur if the suggested frequency of application is exceeded. Coloring of teeth, dentures and dentures (see section 4.8). Products for topical use, especially if applied for repeated and prolonged periods of time, can give rise to hypersensitivity phenomena. In this case, stop treatment and consult your doctor in order to establish suitable therapy. After a short period of treatment without appreciable results, consult your doctor. Information on excipients This medicine contains 476 mg of ethanol alcohol (alcohol) in each ml, which is equivalent to 59.5% v/v. May cause burning sensation on damaged skin. PYRALVEX is flammable.
INTERACTIONS
Salicylates are highly bound to plasma proteins and can displace other drugs from binding sites. Clinically important interactions may occur with heparin and oral anticoagulants, but these are primarily due to an effect on platelet function, rather than on pharmacokinetic parameters.
SIDE EFFECTS
In the system organ class, undesirable effects are listed in order of frequency (number of patients expected to experience the reaction), using the following convention: Very common (≥1/10); Common (≥1/100, <1/10); Uncommon (≥1/1,000, <1/100); Rare (≥1/10,000, <1/1,000); Very Rare (<1/10,000); Not known (frequency cannot be estimated from the available data). Immune system disorders. Not known: Allergic reactions. Gastrointestinal disorders. Common: Temporary discoloration of the teeth or oral mucosa. Disorders of the skin and subcutaneous tissue. Not known: skin rash and urticaria. Systemic pathologies and conditions relating to the administration site. Very common: Transient local burning sensation at the application site. Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.aifa.gov.it/content/segnalazioni-reazioni-avverse.








